President, North America Pharmaceuticals2009 rank: 37
This Eli Lilly alum's $15-billion-a-year business hinges on its respiratory franchise. The hope: that Relovair, now in clinical trials, replaces Advair, the blockbuster GSK drug whose patent soon expires.
NEXT: Cathie Lesjak
Last updated September 30 2010: 2:47 PM ET